Journal
ONCOTARGETS AND THERAPY
Volume 6, Issue -, Pages 321-324Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S42453
Keywords
EZH2; PRC2; cancer
Categories
Ask authors/readers for more resources
Accumulating evidence shows that enhancer of zeste homolog 2 (E2H2) is upregulated in a broad range of cancer types, such as breast cancer, prostate cancer, ovarian cancer, and colon cancer. Therefore, inhibiting EZH2 expression may be a promising strategy for anticancer therapy. This review focuses on the current understanding of the mechanisms underlying EZH2 regulation that are involved in cancer progression. Also, it introduces two EZH2 inhibitors that target EZH2 and could be potentially applied in the treatment of cancer in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available